Site-specific host gene modification by zinc finger nucleases: pointing the way to drug free control of HIV-1?
- PMID: 25505967
- PMCID: PMC4232064
- DOI: 10.1038/cti.2014.12
Site-specific host gene modification by zinc finger nucleases: pointing the way to drug free control of HIV-1?
Abstract
Anti-retroviral therapy (ART) for human immunodeficiency virus-1 (HIV-1) infection has transformed its clinical course with spectacular reductions in morbidity and mortality, turning this once fatal diagnosis into a manageable chronic infection. However, ART has its limitations. Current ART does not eliminate the virus. Interruption of therapy results in rapid rebound of the virus, and such rebounds are associated with excess morbidity and mortality. This means that therapy once started is for life. This raises the issues of drug resistance due to suboptimal compliance, cumulative toxicities and mounting costs. Efforts to control the virus through novel interventions, particularly through cell or gene therapy have had a resurgence of interest as a single patient was apparently cured by an allogeneic stem cell transplantation from a donor who carried homozygous mutations that disable expression of the HIV-1 co-receptor CCR5. This paper reviews the state of play of gene therapy for HIV infection in the context of a recent paper showing the safety and feasibility of an approach that involves the ex vivo disruption of the ccr5 gene in autologous CD4 T cells using a virally delivered zinc finger nuclease, before their expansion and reinfusion. Although there are still considerable challenges, this approach may point towards a future drug free therapy for HIV-1 infection.
Similar articles
-
Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells.Mol Ther Methods Clin Dev. 2016 Nov 9;3:16067. doi: 10.1038/mtm.2016.67. eCollection 2016. Mol Ther Methods Clin Dev. 2016. PMID: 27900346 Free PMC article.
-
[Deep lung--cellular reaction to HIV].Rev Port Pneumol. 2007 Mar-Apr;13(2):175-212. Rev Port Pneumol. 2007. PMID: 17492233 Review. Portuguese.
-
CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape.Viruses. 2015 Jul 27;7(8):4186-203. doi: 10.3390/v7082816. Viruses. 2015. PMID: 26225991 Free PMC article. Review.
-
Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.J Virol. 2017 Jan 18;91(3):e01389-16. doi: 10.1128/JVI.01389-16. Print 2017 Feb 1. J Virol. 2017. PMID: 27881659 Free PMC article.
-
Gene Editing of HIV-1 Co-receptors to Prevent and/or Cure Virus Infection.Front Microbiol. 2018 Dec 17;9:2940. doi: 10.3389/fmicb.2018.02940. eCollection 2018. Front Microbiol. 2018. PMID: 30619107 Free PMC article. Review.
Cited by
-
HIV-1 CCR5 gene therapy will fail unless it is combined with a suicide gene.Sci Rep. 2015 Dec 17;5:18088. doi: 10.1038/srep18088. Sci Rep. 2015. PMID: 26674113 Free PMC article.
-
Structural and molecular bases of rod photoreceptor morphogenesis and disease.Prog Retin Eye Res. 2016 Nov;55:32-51. doi: 10.1016/j.preteyeres.2016.06.002. Epub 2016 Jun 22. Prog Retin Eye Res. 2016. PMID: 27352937 Free PMC article. Review.
References
-
- World Health Organization/UNICEF/UNAIDS WH Global update on HIV treatment 2013: results, impact and opportunities.2013
-
- Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093–2099. - PubMed
-
- Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423–1430. - PubMed
-
- El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. New Engl J Med. 2006;355:2283–2296. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials